Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(ε-caprolactone) copolymer micelle for combination cancer chemotherapy

Yan, Tingsheng; Li, Dalong; Li, Jiwei; Cheng, Feng; Cheng, Jason Chia‐Hsien; Huang, Yudong; He, Jinmei

doi:10.1016/j.colsurfb.2016.05.070

Cited by 60 publications

(30 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To address this problem, anti-cancer drugs have been encapsulated into nanoparticles (NPs). NPs can improve the therapeutic efficacy of drugs by increasing their halflife in the blood circulation, facilitating their cell penetration and intra-cellular distribution, and decreasing their side effects on normal tissues and cells (Bronze-Uhle et al 2017;She et al 2013;Yan et al 2016).…”

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells

et al. 2019

View full text Add to dashboard Cite

The adaptive treatment tolerance (ATT) of cancer cells is the main encumbrance to cancer chemotherapy. A potential solution to this problem is to treat cancer cells with multiple drugs using nanoparticles (NPs).In this study, we tested the co-administration of curcumin (Cur) and doxorubicin (Dox) to MCF-7 resistant breast cancer cells to block the ATTand elicit efficient cell killing. Drugs were co-administered to cells both sequentially and simultaneously. Sequential drug co-administration was carried out by pre-treating the cells with albumin nanoparticles (ANPs) loaded with Cur (Cur@ANPs) followed by treatment with Dox-loaded ANPs (Dox@ANPs). Simultaneous drug co-administration was carried out by treating the cells with ANPs loaded with both the drugs (Cur/Dox@ANPs). We found that the simultaneous drug co-administration led to a greater intra-cellular accumulation of Dox and cell killing with respect to the sequential drug co-administration. However, the simultaneous drug co-administration led to a lower intracellular accumulation of Cur with respect to the sequential drug co-administration. We showed that this result was due to the aggregation and entrapment of Cur in the lysosomes as soon as it was released from Cur@ANPs, a phenomenon called lysosomotropism. In contrast, the simultaneous release of Dox and Cur from Cur/Dox@ANPs into the lysosomes led to lysosomal pH elevation, which, in turn, avoided Cur aggregation, led to lysosome swelling and drug release in the cytosol, and finally provoked efficient cell killing. Our study shed the light on the molecular processes driving the therapeutic effects of anti-cancer drugs co-administered to cancer cells in different manners. Biophysics ReportsRESULTS AND DISCUSSION Preparation and characterization of albumin nanoparticles loaded with Cur and/or Dox Bovine serum albumin (BSA) nanoparticles (ANPs) loaded with Cur (Cur@ANPs), Dox (Dox@ANPs), or both RESEARCH ARTICLE S. M. Motevalli et al.

show abstract

Section: Introductionmentioning

confidence: 99%

Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Up to the present, several studies have emphasized the superior anticancer efficacy of the DOX-CUR association co-delivered by various nanoparticulate systems, including lipid nanoparticles,8 polymeric nanoparticles,27 polymeric or lipidic micelles24,26,28–30 and liposomes,25 to hepatic, brain and breast cancer, leukemia and melanoma. Therefore, developing a drug delivery system such as liposomes can provide a solution to the aforementioned challenges, by decreasing the toxicity of DOX, enhancing the solubility of CUR and overall improving the stability of both the drugs.…”

Section: Introductionmentioning

confidence: 99%

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

Tefas

Sylvester

Tomuță

et al. 2017

DDDT

115

View full text Add to dashboard Cite

The aim of this work was to use the quality-by-design (QbD) approach in the development of long-circulating liposomes co-loaded with curcumin (CUR) and doxorubicin (DOX) and to evaluate the cytotoxic potential of these liposomes in vitro using C26 murine colon carcinoma cell line. Based on a risk assessment, six parameters, namely the phospholipid, CUR and DOX concentrations, the phospholipid:cholesterol molar ratio, the temperature during the evaporation and hydration steps and the pH of the phosphate buffer, were identified as potential risk factors for the quality of the final product. The influence of these variables on the critical quality attributes of the co-loaded liposomal CUR and DOX was investigated: particle size, zeta potential, drug loading and entrapment efficiency. For this, a 26−2 factorial design was employed to establish a proper regression model and to generate the contour plots for the responses. The obtained data served to establish the design space for which different combinations of variables yielded liposomes with characteristics within predefined specifications. The validation of the model was carried out by preparing two liposomal formulations corresponding to the robust set point from within the design space and one outside the design space and calculating the percentage bias between the predicted and actual experimental results. The in vitro antiproliferative test showed that at higher CUR concentrations, the liposomes co-encapsulating CUR and DOX had a greater cytotoxic effect than DOX-loaded liposomes. Overall, this study showed that QbD is a useful instrument for controlling and optimizing the manufacturing process of liposomes co-loaded with CUR and DOX and that this nanoparticulate system possesses a great potential for use in colon cancer therapy.

show abstract

“…262,263 Glycyrrhizin, glycyrrhetinic acid, and mannose can serve as the guiding group in liver-targeted drug-delivery systems, with good potential. [264][265][266][267][268][269][270] As natural endogenous ligands, bile acids have good biocompatibility and are ideal routes for targeting hepatocellular cancer. 271 In addition, sialic acid, 272 International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 44.224.250.200 on 02-Oct-2020 For personal use only.…”

Section: Low-density Lipoprotein-modified Nanocarriersmentioning

confidence: 99%

<p>Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment</p>

Fan

et al. 2019

IJN

View full text Add to dashboard Cite

Cancer is a major public health problem, and is now the world's leading cause of death. Traditional Chinese medicine (TCM)-combination therapy is a new treatment approach and a vital therapeutic strategy for cancer, as it exhibits promising antitumor potential. Nanotargeted drug-delivery systems have remarkable advantages and allow the development of TCM-combination therapies by systematically controlling drug release and delivering drugs to solid tumors. In this review, the anticancer activity of TCM compounds is introduced. The combined use of TCM for antitumor treatment is analyzed and summarized. These combination therapies, using a single nanocarrier system, namely codelivery, are analyzed, issues that require attention are determined, and future perspectives are identified. We carried out a systematic review of .280 studies published in PubMed since 1985 (no patents involved), in order to provide a few basic considerations in terms of the design principles and management of targeted nanotechnology-based TCM-combination therapies.

show abstract

Effective co-delivery of doxorubicin and curcumin using a glycyrrhetinic acid-modified chitosan-cystamine-poly(ε-caprolactone) copolymer micelle for combination cancer chemotherapy

Cited by 60 publications

References 48 publications

Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells

Co-encapsulation of curcumin and doxorubicin in albumin nanoparticles blocks the adaptive treatment tolerance of cancer cells

Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach

<p>Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment</p>

Contact Info

Product

Resources

About